Moxonidine (physiotens)
Centrally acting. Not unpopular in KSA. Works. Dose: Start 0.2 mg qd (Max 0.4 mg qd). Don’t combine with HTZ, arrythmias, eGFR <60. MOXCON trial : inc mortality in Heart failure given Moxonidine. Does improve insulin resistance but not by much (-0.2 mmol/l).
Package insert. Agonist of imidazoline receptor subtype 1 (I1) found in medulla oblangata. Compared to the older central-acting antihypertensives, moxonidine binds with much greater affinity to the imidazoline I1-receptor than to the α2-receptor. In contrast, clonidine binds to both receptors with equal affinity.
Disclaimer
Do not use the above information to self treat! These are meant as a place for me to jot my obervations and notes down rather than on scraps of paper all over the place. If you feel ou may benefit seek the help of a doctor and discuss any ideas you have with him/her.
